Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 20/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 18/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 18/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 16/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304322 | 0.86 | OPRL1 (0.72) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2778830 | 0.86 | OPRL1 (0.72) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL304093 | 0.74 | OPRL1 (0.75) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL541284 | 0.74 | OPRL1 (0.75) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL15893381 | 0.74 | OPRL1 (0.64) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2707046 | 0.73 | LMNA (0.63) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL303920 | 0.73 | LMNA (0.63) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2842642 | 0.73 | OPRL1 (0.70) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL7696081 | 0.72 | OPRL1 (0.73) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL628105 | 0.71 | LMNA (0.65) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | OPRL1 4248/4885OPRM1 2812/4885OPRK1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.